



# SUNESIS

## Sunesis Pharmaceuticals to Host Conference Call on May 8th to Discuss First Quarter 2019 Financial Results and Recent Highlights

May 1, 2019

SOUTH SAN FRANCISCO, Calif., May 01, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Wednesday, May 8<sup>th</sup>, 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the first quarter ended March 31, 2019.

The call can be accessed by dialing (844) 296-7720 (U.S. and Canada) or (574) 990-1148 (International) and entering passcode 1396684.

To access the live audio webcast, or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at <http://ir.sunesis.com>. The webcast will be recorded and available for replay on the company's website for two weeks.

### About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company developing new therapeutics for the treatment of hematologic and solid cancers. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase inhibitor pipeline, with an emphasis on its oral non-covalent BTK inhibitor ibrutinib. Ibrutinib is currently being evaluated in a Phase 1b/2 study in adults with chronic lymphocytic leukemia and other B-cell malignancies that have progressed after prior therapies. The Company's proprietary PDK1 inhibitor SNS-510 is in preclinical development. PDK1 is a master kinase that activates other kinases important to cell growth and survival including members of the AKT, PKC, RSK, and SGK families. Sunesis is exploring strategic alternatives for vosaroxin, a late-stage investigational product for relapsed or refractory AML. Sunesis also has an interest in the pan-RAF inhibitor TAK-580 which is licensed to Takeda. TAK-580 is in a clinical trial for pediatric low-grade glioma.

For additional information on Sunesis, please visit [www.sunesis.com](http://www.sunesis.com).

SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.

#### Investor and Media Inquiries:

Maeve Conneighton  
Argot Partners  
212-600-1902

Willie Quinn  
Sunesis Pharmaceuticals Inc.  
650-266-3716



# SUNESIS

Source: Sunesis Pharmaceuticals, Inc.